PetMed Express, Inc. (NASDAQ:PETS) Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. lifted its position in PetMed Express, Inc. (NASDAQ:PETS - Free Report) by 355.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 106,954 shares of the company's stock after purchasing an additional 83,473 shares during the quarter. JPMorgan Chase & Co. owned about 0.52% of PetMed Express worth $516,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. American Century Companies Inc. increased its stake in PetMed Express by 15.3% in the fourth quarter. American Century Companies Inc. now owns 33,662 shares of the company's stock worth $162,000 after purchasing an additional 4,459 shares during the period. R Squared Ltd purchased a new stake in shares of PetMed Express in the 4th quarter worth approximately $31,000. Finally, Virtu Financial LLC bought a new stake in PetMed Express during the fourth quarter valued at about $58,000. 73.33% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on PETS. Morgan Stanley lowered their target price on shares of PetMed Express from $3.50 to $3.20 and set an "underweight" rating for the company in a research note on Thursday, April 17th. StockNews.com downgraded PetMed Express from a "buy" rating to a "hold" rating in a report on Wednesday, April 23rd.

PetMed Express Stock Down 1.7 %

Shares of PETS stock traded down $0.06 during mid-day trading on Tuesday, hitting $3.54. 83,013 shares of the stock were exchanged, compared to its average volume of 287,463. The company has a market cap of $73.12 million, a PE ratio of 354.35 and a beta of 0.76. PetMed Express, Inc. has a 52-week low of $2.90 and a 52-week high of $6.85. The firm has a fifty day moving average of $3.69 and a 200 day moving average of $4.44.

PetMed Express (NASDAQ:PETS - Get Free Report) last issued its earnings results on Monday, February 10th. The company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.02). PetMed Express had a net margin of 0.14% and a return on equity of 0.37%. Equities analysts predict that PetMed Express, Inc. will post 0.19 EPS for the current year.

Insider Transactions at PetMed Express

In other PetMed Express news, CEO Sandra Yvette Campos sold 60,463 shares of PetMed Express stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $3.31, for a total transaction of $200,132.53. Following the transaction, the chief executive officer now directly owns 578,524 shares of the company's stock, valued at $1,914,914.44. The trade was a 9.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.10% of the company's stock.

PetMed Express Company Profile

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.